Compare Moderna, Inc. (MRNA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VF Corp — how do they compare? Moderna, Inc. trades at $60.6 (market cap $23.88B), while VF Corp trades at $14.78 (market cap $5.86B). The key difference: Moderna, Inc. is far larger — about 4.1× VF Corp's market cap, and VF Corp pays a 2.42% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VFC | |
|---|---|---|
Market Cap | $23.88B | $5.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $21.55 |
52-Week Low | $22.36 | $12.21 |
Enterprise Value | $20.03B | $10.14B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.
The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.
VFC trades at $14.99, up 1.63% on the day, with a bearish technical signal and mixed earnings. Recent Q1 2027 results missed EPS estimates, though revenue exceeded expectations. The company faces challenges with Vans brand performance and a CFO transition, but maintains a raised fiscal 2027 sales outlook. Cash flow trends show improvement in 2026, with net cash flow turning positive.
Outlook remains cautious due to weak consumer sentiment and brand-specific headwinds, but deleveraging progress and margin gains offer potential upside. Risks include persistent Vans drag and macro pressures. Analyst consensus is Hold with a $17.44 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
